Cero Therapeutics Holdings, Inc. Files 8-K
Ticker: CEROW · Form: 8-K · Filed: Jan 7, 2025 · CIK: 1870404
Sentiment: neutral
Topics: corporate-update, name-change
TL;DR
Cero Therapeutics (fka Phoenix Biotech) filed an 8-K on Jan 7, 2025, confirming its corporate details.
AI Summary
On January 7, 2025, Cero Therapeutics Holdings, Inc. filed an 8-K report. The filing indicates the company's former name was Phoenix Biotech Acquisition Corp., with a name change occurring on June 30, 2021. The company is incorporated in Delaware and its fiscal year ends on December 31.
Why It Matters
This filing provides official confirmation of Cero Therapeutics Holdings, Inc.'s corporate identity and history, including its previous name, which is important for tracking its evolution and potential future disclosures.
Risk Assessment
Risk Level: low — This filing is a routine corporate update and does not contain new financial or operational information that would typically indicate a change in risk.
Key Players & Entities
- CERO THERAPEUTICS HOLDINGS, INC. (company) — Registrant
- Phoenix Biotech Acquisition Corp. (company) — Former name
- January 7, 2025 (date) — Date of earliest event reported
- June 30, 2021 (date) — Date of name change
- Delaware (jurisdiction) — State of incorporation
FAQ
What is the primary purpose of this 8-K filing for Cero Therapeutics Holdings, Inc.?
The primary purpose of this 8-K filing is to report current information as required by the SEC, specifically detailing the company's corporate identity and history, including its former name and date of name change.
When did Cero Therapeutics Holdings, Inc. officially change its name?
Cero Therapeutics Holdings, Inc. officially changed its name on June 30, 2021.
What was Cero Therapeutics Holdings, Inc. previously known as?
Cero Therapeutics Holdings, Inc. was previously known as Phoenix Biotech Acquisition Corp.
In which state is Cero Therapeutics Holdings, Inc. incorporated?
Cero Therapeutics Holdings, Inc. is incorporated in Delaware.
What is the SIC code for Cero Therapeutics Holdings, Inc.?
The Standard Industrial Classification (SIC) code for Cero Therapeutics Holdings, Inc. is 2836, which corresponds to Biological Products (No Diagnostic Substances).
Filing Stats: 476 words · 2 min read · ~2 pages · Grade level 13.2 · Accepted 2025-01-07 16:30:09
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share CERO NASDAQ Global Market
- $5.463 million — reports a cash balance of approximately $5.463 million as of January 7, 2025. 1 SIGNATURES
Filing Documents
- ea0227074-8k_cerotherap.htm (8-K) — 28KB
- 0001213900-25-001663.txt ( ) — 242KB
- cero-20250107.xsd (EX-101.SCH) — 4KB
- cero-20250107_def.xml (EX-101.DEF) — 26KB
- cero-20250107_lab.xml (EX-101.LAB) — 36KB
- cero-20250107_pre.xml (EX-101.PRE) — 25KB
- ea0227074-8k_cerotherap_htm.xml (XML) — 6KB
01 Other Events
Item 8.01 Other Events. Reference is hereby made to the Current Report on Form 8-K filed by CERo Therapeutics Holdings, Inc. (the "Company") on December 31, 2024, pursuant to which the Company reported the receipt of proceeds exercises of certain warrants to purchase shares of Series A Preferred Stock and issuances of shares pursuant to the Company's committed equity financing facility (the "Equity Line") through December 30, 2024. As a result of the receipt of such proceeds and the receipt of additional proceeds from sales pursuant to the Equity Line through January 6, 2025, the Company now reports a cash balance of approximately $5.463 million as of January 7, 2025. 1
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: January 7, 2025 CERO THERAPEUTICS HOLDINGS, INC. By: /s/ Chris Ehrlich Name: Chris Ehrlich Title: Chief Executive Officer 2